Sato Hirotoshi, Ito Chihiro, Tashiro Manabu, Hiraoka Kotaro, Shibuya Katsuhiko, Funaki Yoshihito, Iwata Ren, Matsuoka Hiroo, Yanai Kazuhiko
Department of Psychiatry, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan,
Psychopharmacology (Berl). 2013 Nov;230(2):227-34. doi: 10.1007/s00213-013-3146-1. Epub 2013 Jun 1.
Histamine H₁ antagonists have hypnotic, appetite-promoting, and sedative effects. The affinities of various antidepressants for histamine receptors have only been partially determined in vitro and animal study. Positron emission tomography (PET) can clarify the in vivo dynamics of antidepressants at histamine receptors.
We performed human PET imaging with [¹¹C]doxepin, a selective PET ligand of the histamine H₁ receptor (H₁R), to study the in vivo affinities of fluvoxamine and mirtazapine for the H₁R.
The subjects were five male healthy Japanese volunteers. We performed cross-randomized PET imaging after single oral administration of fluvoxamine (25mg), mirtazapine (15 mg), or placebo. PET data were analyzed by region-of-interest and voxel-by-voxel analysis. We concurrently measured plasma drug concentrations, using liquid chromatography/tandem mass spectrometry and subjective sleepiness.
The binding potential ratio of mirtazapine in brain cortex was significantly lower than that of fluvoxamine or placebo. Fluvoxamine did not occupy the H₁R, whereas H₁R occupancy (H₁RO) of mirtazapine reached 80-90 % in the cerebral neocortex. In the voxel-by-voxel analysis, the binding potential of mirtazapine was significantly lower than placebo in the dorsolateral prefrontal cortex, lateral temporal cortex, anterior cingulate gyrus, and posterior cingulate gyrus. The H₁RO of mirtazapine depended on the plasma drug concentration (AUC(0-180 min)) and was related to subjective sleepiness.
Our results demonstrate a low affinity of fluvoxamine and a very high affinity of mirtazapine for the human brain H₁R in vivo. This study provides a basis for investigating the efficacy of new-generation antidepressants in central histamine systems.
组胺H₁拮抗剂具有催眠、促进食欲和镇静作用。各种抗抑郁药对组胺受体的亲和力仅在体外和动物研究中得到部分确定。正电子发射断层扫描(PET)可以阐明抗抑郁药在组胺受体上的体内动力学。
我们使用组胺H₁受体(H₁R)的选择性PET配体[¹¹C]多塞平进行人体PET成像,以研究氟伏沙明和米氮平对H₁R的体内亲和力。
受试者为五名健康的日本男性志愿者。在单次口服氟伏沙明(25mg)、米氮平(15mg)或安慰剂后,我们进行了交叉随机PET成像。PET数据通过感兴趣区分析和逐像素分析进行分析。我们同时使用液相色谱/串联质谱法测量血浆药物浓度和主观嗜睡程度。
米氮平在脑皮质中的结合潜能比值显著低于氟伏沙明或安慰剂。氟伏沙明不占据H₁R,而米氮平在大脑新皮质中的H₁R占有率(H₁RO)达到80-90%。在逐像素分析中,米氮平在背外侧前额叶皮质、颞叶外侧皮质、前扣带回和后扣带回中的结合潜能显著低于安慰剂。米氮平的H₁RO取决于血浆药物浓度(AUC(0-180分钟)),并与主观嗜睡程度相关。
我们的结果表明,氟伏沙明对人脑H₁R的亲和力较低,而米氮平的亲和力非常高。这项研究为研究新一代抗抑郁药在中枢组胺系统中的疗效提供了基础。